Euro Surveill This is an RSS file. You can use it to subscribe to this data in your favourite RSS reader or to display this data on your own website or blog.

Clinical isolates of ST131 bla OXA-244-positive Escherichia coli , Italy, December 2022 to July 2023
We report clinical isolates of OXA-244-producing ST131 E. coli in four patients admitted to an acute care hospital in Pavia, Italy. The association of this difficult-to-detect determinant with a globally circulating high-risk clone, ST131 E. coli, is of clinical relevance.PMID:38390649 | DOI:10.2807/1560-7917.ES.2024.29.8.2400073 (Source: Euro Surveill)
Source: Euro Surveill - February 23, 2024 Category: Infectious Diseases Authors: Aurora Piazza Marta Corbella Vittoria Mattioni Marchetti Cristina Merla Irene Mileto Angela Kuka Greta Petazzoni Stefano Gaiarsa Roberta Migliavacca Fausto Baldanti Patrizia Cambieri Source Type: research

Application of the screening method for estimating COVID-19 vaccine effectiveness using routine surveillance data: Germany's experience during the COVID-19 pandemic, July 2021 to March 2023
Euro Surveill. 2024 Feb;29(8). doi: 10.2807/1560-7917.ES.2023.29.8.2300329.ABSTRACTThe screening method represents a simple, quick, and practical tool for estimating vaccine effectiveness (VE) using routine disease surveillance and vaccine coverage data, even if these data cannot be linked. In Germany, where notification data, laboratory testing data, and vaccine coverage data cannot be linked due to strict data protection requirements, the screening method was used to assess COVID-19 VE continuously between July 2021 and March 2023. During this period, when Delta and Omicron variants circulated, VE estimates were produced...
Source: Euro Surveill - February 23, 2024 Category: Infectious Diseases Authors: Nita Perumal Viktoria Sch önfeld Ole Wichmann Source Type: research

Interim 2023/24 influenza A vaccine effectiveness: VEBIS European primary care and hospital multicentre studies, September 2023 to January 2024
Euro Surveill. 2024 Feb;29(8). doi: 10.2807/1560-7917.ES.2024.29.8.2400089.ABSTRACTInfluenza A viruses circulated in Europe from September 2023 to January 2024, with influenza A(H1N1)pdm09 predominance. We provide interim 2023/24 influenza vaccine effectiveness (IVE) estimates from two European studies, covering 10 countries across primary care (EU-PC) and hospital (EU-H) settings. Interim IVE was higher against A(H1N1)pdm09 than A(H3N2): EU-PC influenza A(H1N1)pdm09 IVE was 53% (95% CI: 41 to 63) and 30% (95% CI: -3 to 54) against influenza A(H3N2). For EU-H, these were 44% (95% CI: 30 to 55) and 14% (95% CI: -32 to 43), ...
Source: Euro Surveill - February 23, 2024 Category: Infectious Diseases Authors: Marine Maurel Jennifer Howard Esther Kissling Francisco Pozo Gloria P érez-Gimeno Silke Buda No émie Sève Adele McKenna Adam Meijer Ana Paula Rodrigues Iv án Martínez-Baz Ivan Mlinari ć Neus Latorre-Margalef Gerg ő Túri Mihaela Laz ăr Clara Mazag Source Type: research

Measuring waning protection from seasonal influenza vaccination during nine influenza seasons, Ontario, Canada, 2010/11 to 2018/19
ConclusionsInfluenza vaccine protection wanes during an influenza season. Understanding the optimal timing of vaccination could ensure robust protection during seasonal influenza activity.PMID:38390652 | DOI:10.2807/1560-7917.ES.2024.29.8.2300239 (Source: Euro Surveill)
Source: Euro Surveill - February 23, 2024 Category: Infectious Diseases Authors: Hannah Chung Michael A Campitelli Sarah A Buchan Aaron Campigotto Natasha S Crowcroft Jonathan B Gubbay James Kh Jung Timothy Karnauchow Kevin Katz Allison J McGeer J Dayre McNally David C Richardson Susan E Richardson Laura C Rosella Margaret L Russell K Source Type: research

2023/24 mid-season influenza and Omicron XBB.1.5 vaccine effectiveness estimates from the Canadian Sentinel Practitioner Surveillance Network (SPSN)
Euro Surveill. 2024 Feb;29(7). doi: 10.2807/1560-7917.ES.2024.29.7.2400076.ABSTRACTThe Canadian Sentinel Practitioner Surveillance Network reports mid-season 2023/24 influenza vaccine effectiveness (VE) of 63% (95% CI: 51-72) against influenza A(H1N1)pdm09, lower for clade 5a.2a.1 (56%; 95% CI: 33-71) than clade 5a.2a (67%; 95% CI: 48-80), and lowest against influenza A(H3N2) (40%; 95% CI: 5-61). The Omicron XBB.1.5 vaccine protected comparably well, with VE of 47% (95% CI: 21-65) against medically attended COVID-19, higher among people reporting a prior confirmed SARS-CoV-2 infection at 67% (95% CI: 28-85).PMID:38362622 |...
Source: Euro Surveill - February 16, 2024 Category: Infectious Diseases Authors: Danuta M Skowronski Yuping Zhan Samantha E Kaweski Suzana Sabaiduc Ayisha Khalid Romy Olsha Sara Carazo James A Dickinson Richard G Mather Hugues Charest Agatha N Jassem In ès Levade Maan Hasso Nathan Zelyas Ruimin Gao Nathalie Bastien Source Type: research

Letter to the editor: Further identification of a measles variant displaying mutations impacting molecular diagnostics, Northern Italy, 2024
Euro Surveill. 2024 Feb;29(7). doi: 10.2807/1560-7917.ES.2023.29.7.2400079.NO ABSTRACTPMID:38362623 | DOI:10.2807/1560-7917.ES.2023.29.7.2400079 (Source: Euro Surveill)
Source: Euro Surveill - February 16, 2024 Category: Infectious Diseases Authors: Clara Fappani Maria Gori Silvia Bianchi Marta Canuti Daniela Colzani Melissa Baggieri Silvia Gioacchini Emilio D'Ugo Elisabetta Tanzi Fabio Magurano Antonella Amendola Source Type: research

Epidemiology of reported cases of leptospirosis in the EU/EEA, 2010 to 2021
ConclusionThe notification rate of leptospirosis at EU/EEA level increased during 2010-2021 despite including the first 2 years of the COVID-19 pandemic and associated changes in population behaviours. Studies at (sub)national level would help broaden the understanding of differences at country-level and specificities in terms of exposure to Leptospira, as well as biases in diagnosis and reporting.PMID:38362624 | DOI:10.2807/1560-7917.ES.2024.29.7.2300266 (Source: Euro Surveill)
Source: Euro Surveill - February 16, 2024 Category: Infectious Diseases Authors: Julien Beaut é Francesco Innocenti Aristos Aristodimou Michaela Špačková Caroline Eves Natalia Kerbo Ruska Rimhanen-Finne Mathieu Picardeau Mirko Faber Georgios Dougas Anna Margr ét Halldórsdóttir Sarah Jackson Viktorija Leit ēna Anne Vergison Mar Source Type: research

Gonorrhoea on the rise in Denmark since 2022: distinct clones drive increase in heterosexual individuals
Euro Surveill. 2024 Feb;29(7). doi: 10.2807/1560-7917.ES.2024.29.7.2400059.ABSTRACTA surge in gonorrhoea in Denmark has occurred since 2022, a 46% increase from 2021. National surveillance, leveraging mandatory reporting and epidemiological data, highlights three distinct clades linked to heterosexual transmission. Despite the rise, these exhibit high susceptibility, contrasting MSM-associated strains. Geographical hotspots and age-specific patterns further illuminate transmission dynamics. The combination of genomic and epidemiological data provides novel insights into the evolving landscape of gonorrhoea, indicating pote...
Source: Euro Surveill - February 16, 2024 Category: Infectious Diseases Authors: Thomas Roland Pedersen Maria Wessman Mikkel Lindegaard S øren Hallstrøm Casper Westergaard Inger Brock Esad Dzajic Dennis Back Holmgaard Christian Salg ård Jensen Ulrik Stenz Justesen Jette Brommann Kornum Turid Snekloth S øndergaard Marianne Kragh Th Source Type: research

Estimation of antimicrobial resistance of Mycoplasma genitalium, Belgium, 2022
ConclusionAlthough limited in sample size, our data suggest no additional benefit of testing MG retrieved from MSM for macrolide resistance in Belgium, when making treatment decisions. The lower occurrence of macrolide resistance in other population groups, combined with emergence of fluoroquinolone RAMs support macrolide-resistance testing in these groups. Continued surveillance of resistance in MG in different population groups will be crucial to confirm our findings and to guide national testing and treatment strategies.PMID:38362626 | DOI:10.2807/1560-7917.ES.2024.29.7.2300318 (Source: Euro Surveill)
Source: Euro Surveill - February 16, 2024 Category: Infectious Diseases Authors: Irith De Baetselier Hilde Smet Kaat Kehoe Imelda Loosen Marijke Reynders Iqbal Mansoor Lorenzo Filippin Mathieu Cauchie Ellen Van Even Nadia Makki Gilberte Schiettekatte Wouter Vandewal Bart Glibert Veerle Matheeussen Yolien Van der Beken Reinoud Cartuyve Source Type: research

Bias in vaccine effectiveness studies of clinically severe outcomes that are measured with low specificity: the example of COVID-19-related hospitalisation
Euro Surveill. 2024 Feb;29(7). doi: 10.2807/1560-7917.ES.2024.29.7.2300259.ABSTRACTMany vaccine effectiveness (VE) analyses of severe disease outcomes such as hospitalisation and death include 'false' cases that are not actually caused by the infection or disease under study. While the inclusion of such false cases inflate outcome rates in both vaccinated and unvaccinated populations, it is less obvious how they affect estimates of VE. Illustrating the main points through simple examples, this article shows how VE is underestimated when false cases are included as outcomes. Depending how the outcome indicator is defined, e...
Source: Euro Surveill - February 16, 2024 Category: Infectious Diseases Authors: Christian Holm Hansen Source Type: research